中药达明饮治疗非增殖期糖尿病视网膜病变的临床实验研究
|
摘要
目的:评价达明饮治疗非增殖期糖尿病视网膜病变的有效性,探讨达明饮益气养阴,化瘀止血的作用机制。
方法:临床采集Ⅱ型糖尿病并发糖尿病视网膜病变非增殖期眼底改变患者32例(64只眼),按随机原则采用分组治疗的方法,治疗组口服中药达明饮,对照组口服导升明。治疗前和治疗1个月后分别对患者进行视力、眼底照相及眼底荧光造影、视野及双眼彩色多普勒血流成像检查,客观评判治疗效果。
结果:(1)两组治疗后治疗组总有效率为93.57%,对照组总有效率为71.43%,治疗组优于对照组(P＜0.05)。(2)眼底检查及荧光造影比较,治疗组优于对照组,治疗组总有效率为93.75%,导升明组总有效率为75%,组间比较有统计学意义(P＜0.05)。(3)视野:治疗组治疗前后差异有统计学意义(P＜0.05),对照组治疗后视野有好转,但无统计学意义(P＞0.05)。用药后两组组间比较,有统计学意义(P＜0.05)。(4)两组治疗后视网膜血流均有改善,治疗组组内比较PSV、EDV均有统计学意义(P＜0.05),对照组组内比较RI有统计学意义(P＜0.05),PSV、EDV差异无统计学意义(P＞0.05),组间比较PSV、EDV有统计学意义(P＜0.05),RI差异无统计学意义(P＞0.05)。(5)视力结果组内比较差异均有统计学意义(P＜0.05),组间比较无统计学意义(P＞0.05)。
结论:中药达明饮治疗非增殖期糖尿病视网膜病变疗效显著,且优于导升明。
Objective:To evaluate the efficiency of Da Ming Yin for treatment of non-proliferative diabetic retinopathy(NPDR) and investigate the mechanism of Da Ming Yin for Yiqi Yangyin and Huayu Zhixue(supplementing qi, nourishing yin,removing blood stasis).
Methods:32 patients(64 eyes) with typeⅡdiabetes mellitus concurrent with nonproliferative diabetic retinopathy issue of fundus changes were clinically gathered and randomly divided into the treatment group(16 cases) treated with Da Ming Yin and control group(16 cases) treated with Doxium.Curative effects were observed objectively,and visual acuity,fundus photography and fundus fluorescein angiography,visual field and color Doppler flow imaging were detected before and after 1 month's treatment.
Results:(1) After treatment,the total curative effective rate in treatment group was 93.57%,better than that in the control group(71.43%,P＜0.05).(2) Comparison of fundus examination and fluorescein angiography,the treatment group was superior to the control group.The total curative effective rate in treatment group and control group was 93.75%,75%respectively.There was significant difference between the two groups(P＜0.05).(3) Significant difference was shown in the comparison of visual field before and after treatment in the treatment group(P＜0.05).After treatment the visual field was improved in the control group,however,there was no statistical significance (P＞0.05).After treatment there were significant difference between the two groups(P＜0.05).(4) Retinal blood flow was improved in both groups after treatment.There was significant difference in the comparison of PSV,EDV (P＜0.05) in the treatment group.There was significant difference in the comparison of RI(P＜0.05),and no statistical significance in the comparison of PSV,EDV(P＞0.05) in the control group.Significant difference was shown in the comparison of PSV,EDV(P＜0.05),and no statistical significance was shown in the comparison of RI(P＞0.05) between the two groups.(5) There was significant difference in the comparison of visual inspection results in their respective group(P＜0.05) and no statistical significance compared between the two groups(P＞0.05).
Conclusions:The Chinese traditional medicine Da Ming Yin had a significant curative effect on the treatment of non-proliferative diabetic retinopathy.
方法:临床采集Ⅱ型糖尿病并发糖尿病视网膜病变非增殖期眼底改变患者32例(64只眼),按随机原则采用分组治疗的方法,治疗组口服中药达明饮,对照组口服导升明。治疗前和治疗1个月后分别对患者进行视力、眼底照相及眼底荧光造影、视野及双眼彩色多普勒血流成像检查,客观评判治疗效果。
结果:(1)两组治疗后治疗组总有效率为93.57%,对照组总有效率为71.43%,治疗组优于对照组(P＜0.05)。(2)眼底检查及荧光造影比较,治疗组优于对照组,治疗组总有效率为93.75%,导升明组总有效率为75%,组间比较有统计学意义(P＜0.05)。(3)视野:治疗组治疗前后差异有统计学意义(P＜0.05),对照组治疗后视野有好转,但无统计学意义(P＞0.05)。用药后两组组间比较,有统计学意义(P＜0.05)。(4)两组治疗后视网膜血流均有改善,治疗组组内比较PSV、EDV均有统计学意义(P＜0.05),对照组组内比较RI有统计学意义(P＜0.05),PSV、EDV差异无统计学意义(P＞0.05),组间比较PSV、EDV有统计学意义(P＜0.05),RI差异无统计学意义(P＞0.05)。(5)视力结果组内比较差异均有统计学意义(P＜0.05),组间比较无统计学意义(P＞0.05)。
结论:中药达明饮治疗非增殖期糖尿病视网膜病变疗效显著,且优于导升明。
Objective:To evaluate the efficiency of Da Ming Yin for treatment of non-proliferative diabetic retinopathy(NPDR) and investigate the mechanism of Da Ming Yin for Yiqi Yangyin and Huayu Zhixue(supplementing qi, nourishing yin,removing blood stasis).
Methods:32 patients(64 eyes) with typeⅡdiabetes mellitus concurrent with nonproliferative diabetic retinopathy issue of fundus changes were clinically gathered and randomly divided into the treatment group(16 cases) treated with Da Ming Yin and control group(16 cases) treated with Doxium.Curative effects were observed objectively,and visual acuity,fundus photography and fundus fluorescein angiography,visual field and color Doppler flow imaging were detected before and after 1 month's treatment.
Results:(1) After treatment,the total curative effective rate in treatment group was 93.57%,better than that in the control group(71.43%,P＜0.05).(2) Comparison of fundus examination and fluorescein angiography,the treatment group was superior to the control group.The total curative effective rate in treatment group and control group was 93.75%,75%respectively.There was significant difference between the two groups(P＜0.05).(3) Significant difference was shown in the comparison of visual field before and after treatment in the treatment group(P＜0.05).After treatment the visual field was improved in the control group,however,there was no statistical significance (P＞0.05).After treatment there were significant difference between the two groups(P＜0.05).(4) Retinal blood flow was improved in both groups after treatment.There was significant difference in the comparison of PSV,EDV (P＜0.05) in the treatment group.There was significant difference in the comparison of RI(P＜0.05),and no statistical significance in the comparison of PSV,EDV(P＞0.05) in the control group.Significant difference was shown in the comparison of PSV,EDV(P＜0.05),and no statistical significance was shown in the comparison of RI(P＞0.05) between the two groups.(5) There was significant difference in the comparison of visual inspection results in their respective group(P＜0.05) and no statistical significance compared between the two groups(P＞0.05).
Conclusions:The Chinese traditional medicine Da Ming Yin had a significant curative effect on the treatment of non-proliferative diabetic retinopathy.
引文
1 Malone J I,Morrison A D,Pavan P,et al.Prevalence and significance of retinopathy in subjects with 1 diabetes of less than 5 years duration screened for the diabetes control and complications trial[J].Diabetes Care,2001,24:522-526.
2 史轶繁.内分泌和代谢学[M].北京:科学出版社,2000:1343.
3 Xiang H D.The morbitity of chronic complication of Chinese patiens with DM within 1991 - 2000[J].Diabetes Research and Clinical Practice,2000,56(suppl):841.
4 Nakajima M,Cooney M J,Alexander H T,et Al.Normalization of retinal vascular permeability in experimental diabetes with genistein[J].Invest Ophthalmol Vis Sci,2001,42:2110-2114.
5 康洁.糖尿病视网膜病变发生发展与全身相关因素研究进展,国外医学眼科学分册[J].2004,28(2):107-120.
6 曾庆华.中医眼科学[M]新世纪全国高等中医药院校规划教材(供中医药类专业用).北京:中国中医药出版社,2003:201.
7 金·刘守真,河间医集·黄帝素问宣明论方·卷十·燥门·消渴总论.第1版,北京:人民卫生出版社.1998:288
8 李振中,尹翠梅,痰癖互结与糖尿病血管病变[J].中华新医药,2002(1):2.
9 王明芳,谢学军,中医眼科学[M].北京:中国中医药出版社,2004:740.
10 谢学军,王明芳.糖尿病视网膜病变的病机探讨[J].中国中医眼科杂志,1995,5(2):86-88.
11 梁光宇.冯明清教授治疗糖尿病学术思想简介[J].河南中医,2000,(1):15.
12 李劲亮.消渴明目方治疗早期糖尿病性视网膜病变35例[J].国医论坛,2000,15(6):24.
13 刘求红.余杨桂教授治疗糖尿病性视网膜病变的思路与经验[J].黑龙江中医药,2004,18(2):26-27.
14 李振中,尹翠梅,和贵章.糖尿病性视网膜新生血管病因病机和防治探讨[J].江苏中医,2000,21(3):12.
15 刘红娣 姚芳蔚老师治疗糖尿病性视网膜病变的经验[J].中西医结合眼科杂志,1998,16(4):233-234.
16 文晓敏,丁辉,浅谈糖尿病视网膜病变中瘀血病理机制初探[J].山西中医,2003,24(10):959-960.
17 董立均,邵晓颖,中西医结合治疗糖尿病视网膜病变48例分析[J].吉林中医药,2000,14(6):52.
18 陈通文.糖尿病论治的临床研究进展[J].中国中医药信息杂志,2000,(1):18.
19 李志英,余杨桂,张淳,等.糖尿病视网膜病变与血瘀关系的探讨[J].广州中医药大学学报,1999,16(4):275-278.
20 吕仁和,赵进喜,王世东.糖尿病及其并发症的临床研究[J].新中医,2001,33(3):3-5.
21 朱晓林.健脾祛瘀化痰法治疗糖尿病视网膜病变理论探讨[J].中医药学刊,2005,23(7):1291-1292.
22 祁宝玉,廖岩松,等.糖尿病性视网膜病变的研究思路[J].中国中医眼科杂志,1998,8(1):54-55.
23 李志英,余杨桂,张淳,等.糖尿病中医证型与糖尿病视网膜病变分期关系的探讨[J].中国中医眼科杂志,2000,10(1):29-32.
24 张慧,孙河.糖尿病视网膜病变分级与中医辨证分型关系的临床研究[J].中医药学报,2004,32(4):6-7.
25 苏航,吴烈.糖尿病视网膜病变发展与中医证候特征相关性的临床研究[J].中国中医眼科杂志.2005,15(4):190-192.
26 李传课.中西医结合眼科学[M].北京:中国中医药出版社,2001,8:294-295.
27 董彦敏.糖尿病眼病的防治[M].北京:中国中医药出版社,2003,8:83-85.
28 韦企平.韦玉英眼科经验集[M].北京:人民卫生出版社,2001,10:231-232.
29 姚芳蔚.眼底病的中医治疗[M].上海:上海中医药大学出版社,2001:56-57.
30 刘文华,廖品正.糖尿病视网膜病变的病因及分型论治探讨[J].国医论坛,2001,16(3):15-16.
31 刘红娣.姚芳蔚治疗糖尿病视网膜病变的经验[J].中西医结合眼科杂志.1998,16(4):45-46.
32 高璇,李刚.糖尿病视网膜病变的中医治疗[J].中医药信息,2001,18(3):43.
33 李红,夏建生.糖尿病视网膜病变辩证及分型的临床研究进展[J].河南中医,2000,20(5):33.
34 凌波达.中西医结合治疗糖尿病眼底出血[J].北京中医.1999(3):17.
35 吉敏.中西医结合治疗糖尿病视网膜病变27例[J].吉林中医药.2004,24(8):14-16.
36 倪青.著名中医学家林兰教授学术经验之十一病位侧重肝脾肾治宜祛瘀重养阴-治疗糖尿病视网膜病变的经验[J].辽宁中医杂志,2001,28(5):259-261.
37 吴丹巍,殷长青,郑军,等.辨证分型为主治疗糖尿病视网膜病变临床观察[J].上海中医药杂志,2000,34(6):42-43.
38 高培质,增生型糖尿病视网膜病变的中西医结合治疗[J].中国中医眼科杂志,2001,(4):196-197.
39 黄建良,喻干龙.活血化瘀法治疗糖尿病视网膜病变38例[J].湖南中医杂志,2000,16(1):29.
40 刘韵宇,余元泰,杨国栋,滋阴去瘀法治疗糖尿病视网膜病变[J].兰州医学学报,1999,6,25(2)59-61.
41 罗旭升,高健生,朱旭华,交泰丸防治DR的思路探讨[J].中国中医眼科杂志,2005,15(2),103-104.
42 邓海先,等.宁血益明丸治疗糖尿病视网膜病变远期疗效分析[J].中成药,2003,25(3):209-212.
43 邓辉,金明,苑维,等.复方丹参滴丸治疗早期DR的临床观察[J].中国中医眼科杂志,2005,15(2):36.
44 魏冠男,刘仁波,刘炯.益阴活血明目汤治疗糖尿病性视网膜病变52例总结[J].湖南中医杂志,2007,23(1):7-8.
45 李炳茂,李耀峰,刘慧玲.复方大黄制剂治疗糖尿病视网膜病变200例[J].中医杂志,2000,41(2):119.
46 曹淑兰,孙元荣,张北岳.增视胶囊治疗糖尿病视网膜病变疗效观察[J].山东中医杂志,2000,41(2):281-282.
47 李文东.分期辨证单纯型糖尿病性视网膜病变100例临床观察[J].中国中医药科技,2000,7(3):186-187.
48 增敬.中西结合治疗DR34例[J].吉林中医药.2004,24(8):34-35.
49 林日可.降糖复明汤为主治疗糖尿病眼底病变40[J].浙江中医杂志,2003,38(9):387.
50 刘玲,郭霞.糖目清治疗糖尿病视网膜病变临床总结[J].山东中医药杂志,2000,(3):145.
51 侯建宁.养阴化瘀汤治疗糖尿病视网膜病变50例[J].河北中医,2004,26(8):629.
52 罗恒,余红.递法明片联合降糖愈目汤治疗糖尿病视网膜病变47例[J].中华现代眼科学杂志,2004,1(2):168.
53 焦晓燕,曾佩红.自拟益气通脉汤治疗非增殖期糖尿病视网膜病变临床观察[J].北京中医,2005,24(3):162-163.
54 盛萍.坠血明目饮治疗糖尿病视网膜病变48例[J].河南中医,2006,26(1):53-54.
55 杨建华,段俊国,周春阳.糖网方治疗糖尿病视网膜病变101例[J].河南中医,2003,23(10):37-38.
56 于文洲,张伟.糖视明方治疗DR的临床观察[J].山东中医药大学学报,2000,24(5):361-362.
57 齐翠英.降糖明目合剂治疗糖尿病视网膜病变58例[J].河南中医,2002,22(1):39.
58 杨海燕,杨建华.益气活血方治疗糖尿病视网膜病变61眼临床及彩色多谱勒眼动脉血流频数观察[J].浙江中医杂志,2001,(1):30-31.
59 赵红.辨证治疗糖尿病视网膜病变[J].河南中医,2001,21(3):54.
60 张娟.止血愈消汤治疗糖尿病视网膜病变眼底出血36例[J].浙江中医杂志,2006,41(8):474.
61 黄云飞.中西医结合治疗糖尿病视网膜病变70例疗效观察[J].四川中医,2004,22(8):94.
62 徐寒松,孔德明,李雪梅,等.通脉糖眼明胶囊治疗单纯型糖尿病性视网膜病变临床研究[J].中华中医药杂志,2006,21(9):567-569.
63 蒋莉.熊胆逐瘀片治疗非增殖性糖尿病视网膜病变观察[J].辽宁中医杂志,2001,28(4):213-214.
64 孙河,郝晓楠.达明饮治疗糖尿病视网膜病变的临床观察[J].中华医学会第十界全国眼科学术大会论文汇编,2005,9.8-12.
65 于强,张欣,柳青.达纳康对糖尿病视网膜病变眼视网膜光凝术所致眼前段早期改变的干预效果[J].中华眼底病杂志,2001,17(3):187-189.
66 任平,胡惠君,张瑞.葛根素治疗糖尿病视网膜病变的疗效观察[J].中国中西医结合杂志,2000,20(8):574-576.
67 郭俊杰,尹翠梅.葛根素注射液治疗单纯型糖尿病视网膜病变38例[J].中国中医药信息杂志,2001,8(10):57-58.
68 相莉,吴谊青,刘新玲.络泰治疗糖尿病视网膜病变[J].中草药,2000,(4):319.
69 何剑峰,周伟平,仇宣解.糖尿病视网膜病变患者红细胞免疫功能的变化及枸杞子的治疗效应[J].中国中医眼科杂志,1998,8(2):70-73.
70 左宏宇.川芎嗪治疗单纯型糖尿病视网膜病变的临床观察[J].临床眼科杂志,2005,13(3):258-259.
71 唐爱华,史伟,唐农,等.黄芪注射液治疗单纯性糖尿病视网膜病变临床研究[J].浙江中医杂志,2002,38(4):176-177.
72 王为,靡亚兵,陈宝安.汉防己甲素在眼科的基础研究进展[J].中国中医眼科杂志,2001,(1):59-61.
73 郑燕林,王毅,袁晓辉,等.水蛭素对增生性玻璃体视网膜病变影响的组织病理学观察[J].中国中医眼科杂志,2000,10(1):1-3.
74 王坚,陈敏,李晓冬,等.葛根素大黄素对糖基化产物引起牛视网膜微血管周细胞损伤的影响[J].中药药理与临床,2000,16(6):9-10.
75 鹿庆,孙褒忱,王津津.人参皂甙和维生素对氧化损伤的牛细胞凋亡的影响[J].眼科新进展,1999,19(3):152-154.
76 陈少基,李树成.综合治疗单纯性糖尿病视网膜病变的临床研究[J].中国中医眼科杂志,2005,15(2):69-71.
77 刘学敏.针药并用治疗糖尿病视网膜病变60例临床观察[J].上海中医药杂志,2002(2):23.
78 许云祥,张家继.针刺治疗糖尿病研究思路[J].针刺研究,2000,(2):156.
79 呼永河,吴深涛.针药结合治疗糖尿病视网膜病变40例临床观察[J].中国针灸,2003,23(5):259-260.
80 林兰.糖尿病的中西医结合论治,第一版,北京北京科学技术出版社,1998,18(3):138.
81 李菊琦,耳针中药治疗糖尿病性视网膜病变近期观察,河北中医,1998,20(2):8-11.
82 王德全,刘国真,李永春.针刺治疗糖尿病视网膜病变的实验研究[J].中国中医眼科杂志,2000,(3):125-128.
83 姜士军,曹晋宏.川芎嗪离子导入治疗糖尿病视网膜病变疗效观察[J].国际眼科杂志,2006,6(4):941-942.
84 王燕,李志英,余杨桂,等.中药配合眼部川芎嗪直流电离子导入治疗糖尿病视网膜 病变74例疗效观察[J].新中医,2006,38(1):42-43.
85 宋明强,马国政.川芎嗪、维生素B12交替离子导入法治疗糖尿病视网膜病变疗效观察[J].医学理论与实践,2005,18(8):905-907.
86 Asthton N.Vascular basement memberane changes in diabetic retinop2athy[J].Br J Ophthalmol,1974,58:344-366.
87 朱禧星.现代糖尿病学[M].上海:上海医科大学出版社,2000.307-309.
88 Paques M,Massin P,Gaudric A.Growth factors and diabetic retinopa2thy[J].Diabetes Metab,1997,23(2):125-130.
89 Takagi H.Molecular mechanisms of retinal neovascular in diabetetic retinopathy.Intern Meal,2003,(42):299-301.
90 Lieth E,Barber AJ,Xu B,et al.Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy[J].Diabetes,1998,47(5):815-820.
91 Amin RH,Frank RN,Kennedy A,Eliott D,Puklin JE,Abrams GW.Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.Invest Ophthalmol Vis Sci 1997;38:36-47.
92 Lutty GA,McLeod DS,Merges C,Diggs A,Plou(?)t J.Localization of vascular endothelial growth factor in human retina and choroid.Arch Ophthalmol 1996;114:971.
93 Clermont AC,Alello LP,Mori F,et al.Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy medicate retinal hemodynamics in vivo:a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy[J].Am J Ophthalmol,1997,124(4):433-446.
94 侯承花,刘成玉.糖尿病视网膜病变与红细胞变形能力和膜磷脂及收缩蛋白变化的关系[J].中华眼底病杂志,1999,15(3):160-162.
95 何剑峰,仇宜解,周行涛,等.糖尿病视网膜病变与白细胞粘附及变形能力关系的研究[J].眼科研究,2000,18(6):533-535.
96 郭慧丽,付晓美,鲁平,等.载脂蛋白A1、B与糖尿病视网膜病变关系的研究[J].眼科研究,2000,18(5):454-455.
97 Li W,Zhou Q,Qin M,et al.Reduced absolute rate of myo-inositol synthesis of cultured bovine retinal capillary pericytes in high glucose[J].Exp Eye Res,1991,52:569-573.
98 Pfeifer MA,SchumerMP,GelberDA.[J].Diabetes,1997,46(Supp12):82-89.
99 Neuenchwander H.Dose-dependent reduction of retinal vessel changes associated with diabetic retnopathy in galactose-fed dogs by the aldose reductase inhibitor M79175[J].J Ocul Pharmacol Ther,1997,13:517.
100 Alan W,Stit T.The role of advanced glycation in the pathogensis of diabetic retinopathy.Exp Mol Pathology,2003;75:95-108.
101 隋国良,葛在香,董砚虎.糖尿病视网膜病的发病机制及其防治研究进展[J].国外医学·内科学分册,2000;27(3):119-122.
102 李媛,卢艳.糖尿病视网膜病变早期发病机制研究进展[J].国际眼科杂志,2005;5(4):750-754.
103 张小玲,邱曙东,陈艳烔,孙文涛.糖尿病性视网膜病变发病机制研究进展[J].国际眼科杂志.2005;5(6):1239-1241.
104 朱鸿,施彩虹.糖尿病视网膜病变的相关诊断技术展望[J].国际眼科杂志,2005;5(5):1016-1019.
105 Stitt AW,LiYM,GardinerFA,et al[J].Am J Pathol,1997,150(2):523-531.
106 King GL,Shiba T,Oliver J,et al.Cellutar and molecular abnormalities in the vascular endothelium of diabetes mellitua[J].Annu Rev Med,1994,45:175.
107 Ono Y,Umeda F,Kunisaki M,et sl.[J].Diabetologia,1998,41:134-140.
108 Aiello OP,Bursell SE,Clermont A,et al.[J].Diabetes,1997,46:1473-1480.
109 Takag I,Bursell SE,Lin YW,et al.[J].Invest Ophthalmol Vis Sci,1996,37:2504-2518.
110 Hodgkinson AD,Bartlett T,Oates PJ,et al.The response of antioxidant genes to hyperglycemia is abnomal in patients with type 1 diabetes and diabetic nephropathy[J].Diabetes,2003,52:846-851.
111 廖宇洁.氧化应激与糖尿病视网膜病变[J].眼科研究,2007,25(9):710-713.
112 Kowlru RA,Tang J,Kem TS.Abnomalities of retinal metabolism in diabetes and experimental galactosemia.Ⅶ.Effect of long-term administration of antioxidants on the development of retinopathy[J].Diabetes,2001,50,1938-1942.
113 Christinger H W.Crystallization of the receptor binding domain of vascular endothelial growth factor[J].Prteins,1996,26:353-354.
114 Kuroki M,Kawakami M.Diabetic retinopathy-the mechanisms of the ocular neovascularization and development of antiangiogenic drugs[J].Nippon Rinsho,1999,57:584-589.
115 Dawson DW,Volpert OV,Gillis P,et al.Pigment epithelium-derived factor:a potent inhibitor of angiogenesis.Science 1999;285:245.
116 Gao G,Li Y,Zhang D,Gee S,Crosson C,Ma J.Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization.FEBS Lett 2001;489:270.
117 Smith LE,Shen W,Perruzzi C,et al.Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1receptor.Nat Med 1999;5:1390.
118 Smith LEH,Kopchick JJ,Chen W,et al.Essential role of growth hormone in ischemia-induced retinal neovascularization.Science 1997;276:1706-9.
119 Parlapiano C.Study of plasma levels of endothelin - 1 in diabetic patients with arterial hypertension or proliferative retinopathy[J].Minerva Med,1995,86:105.
120 黄敬泽,张珍,王健.外周血循环内皮细胞、血浆内皮素与糖尿病视网膜病变的关系[J].中华眼底病杂志,2000;16(3):1661.
121 胡蜀红,张建华,蔡仕林.糖尿病视网膜病变与血浆内皮素的关系[J].临床荟萃,2003;18(12):677-678.
122 Joussen AM,Poulaki V,Qin W,Kirchhof B,Mitsiades N,Wiegand SJ.Retinal vascular endothelial growth factor induces synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.Am JPathology,2002;160:501-509.
123 Ishida S,Usui T,Yamashirok,Kaji Y,Ahme-d E.VEGF 164 is proinflammatory in the diabetic retina.Invest Opthalmol VisSci,2003;44:2155-2162.
124 Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid.Am J Pathol,1995;147(3):642-653.
125 Mackay C R,Imhof B A.Cell adhesion in the immune system[J].Immunol Today,1993,14:99-102.
126 RadhaV,RernaM,MohanV.Genes and diabetic retinopathy.Indian J Ophthalmol,2002,50:5-11.
127 JoussenAM,Huang S,PoulakiV,etal.In vivoretinalgene expression in early diabetes.Invest Ophthalmol Vis Sci 2001;42(12):3047-3057.
128 刘卫,张勇进.糖尿病性视网膜病变[J].国外医学眼科学分册2005;29(5):352-357.
129 Wilkinson CP,Ferris FL Ⅲ,Klein RE,LeePP,Agardh CD,Davis M.Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.Ophthalomlogy,2003;110(9):1677-1682.
130 刘家琦,李凤鸣.实用眼科学[M].第2版.北京:人民卫生出版社,1999.481.
131 The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 1993;329:977-86.
132 UK Prospective Diabetes Study(UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes(UKPDS 33).Lancet 1998;352:837.
133 Idem.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38.BMJ 1998;317:703-13.
134 Faria JM,Russ H,Costa VP.Retinal nerve fibre layer loss in patients with type 1diabetes mellitus without retinopathy[J].Br J Ophthalmol,2002,86(7):725-728.
135 Brunet J,FarineJC,Garray RP,et al.Angioprotective adtion of calcium dobesilate [J].Fundam Clinpharmacol,1998,12(2):205-212.
136 王另芳,段俊国,张富文.导升明治疗糖尿病性视网膜病变的概况[J].临床眼科杂志,2002,10(2):188-189.
137 M asakazu M et al.The effect of high glucose and aldose reductase inhibitor(FK 366) on myo-inositol uptake in cultured bovine pericyte[J].D iabetes,1998;47(supp 11):A 379.
138 Pfeifer MA et al.Aldose reductase inhibitors:the end ofan era or the need for different trial designs? D iabetes,1997;46(supp 12):S82.
139 罗大卫,许讯.氨基胍与糖尿病视网膜病变[J].眼科新进展,2002,22(3):206.
140 Giardino I et al.Am inoguanidine inhibits reactive oxygen species formation,lipid peroxidation,and oxidant2inducedapop to sis.Diabetes,1998;47:1114.
141 Kern TS,Tang J,Mizutani M,et al.Response of capillary cell death to aminoguanidine predicts the development of retinopathy:comparison of diabetes and galactosemia[J].Invest Ophthalmol Vis Sci,2000,41(12):3972-3978.
142 朱禧星.现代糖尿病学[M].上海:上海医科大学出版社,2000.307-309.
143 Nonaka A,Kiryu J,Tsujikawa A,et al.PKC-beta inhibitor(LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rars[J].Invest Ophthalmol Vis Sci,2000,41(9):2702-2706.
144 Ish ii H et al.Amerlio ration of vascular dysfunctions indiabetic rats by an oral PKC2B inh ibito r.Science,1996;272:728.
145 黄红深.增殖性糖尿病视网膜病变的治疗[J].临床眼科杂志,2002,10(2):146-147.
146 Infeld DA,O'Shea J G.Diabetic retinopathy[J].Postgrad Med J,1998,74:129-133.
147 Cunha Vaz J.Lowering the risk of visual impairment and bindness[J].Diabet Med,1998,15(Supp14):47-50.
148 Fong DS,Ferris FL,Davis MD.Causes of severe visual loss in the early treatment diabetic retinopathy study:ETDRS report no.24 Early Treatment Diabetic Retinpathy Study research group[J].Am Ophthalmol,1999,127(2):137-141.
149 郑筱萸,中药新药治疗糖尿病视网膜病变的临床研究指导原则,北京:中国医药科技出版社.2002,383-385.
150 Klein R,Klein BEK,Moss SE,Davis MD,DeMets DL.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.Ⅱ.Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.Arch Ophthalmol 1984;102:520-6.
151 Idem.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.Ⅲ.Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.Arch Ophthalmol 1984;102:527-32.
152 王平.三七对血液系统作用的研究进展[J].中国野生植物资源,2000,19(1):10.
153 许军,王阶,温林军.三七总皂甙干预血栓形成研究概况[J].云南中医中药杂志,2003,24(5):46.
154 潘莹宇,张建新.中草药活性成分对实验性糖尿病降糖效的研究进展[J].东南大学学报(医学版),2003,22(6):42924.
155 吕萍,陈海峰.三七叶苷降脂作用的实验研究[J].中国生化药物杂志,2004,25(4):235-236.
156 Gibbs A,Greec E,Doctor VM,et al.Isolation and aticoagulant propertiec of polysaccharides of typha angustata and dae monoropsspecies[J].Thromb Res,1983,32(2):27.
157 刘斌,陆蕴如,孙建宁.蒲黄不同炮制品药理活性的比较研究[J].中医药报,1998,20(3):25.
158 王丽君,廖矛川,肖培根.中药蒲黄的化学与药理活性[J].时珍国药研究,1998,9(1):49-50.
159 郑虎占,董泽宏,佘靖,等.中药现代研究与应用,第5卷[M].北京:学苑出版社,1998:4071-4074.
160 全国中草药汇编编写组.全国中草药汇编,上册,第2版[M].北京:人民卫生出版社,2000:800-802.
161 杨新波,黄正明,曹文斌,等.枸杞多糖对正常小白鼠及四氧嘧啶致高血糖的影响[J].人民医药学专刊,1998,14(1):11-13.
162 黄正明,杨新波,曹文斌,等.枸杞多糖对小鼠链佐星性胰岛损伤及血糖的影响[J].世界华人消化杂志,2001,9(12):1419-1421.
163 刘娜,李子良,曹安民.枸杞在保护大鼠视网膜光损伤中作用的研究[J].中华眼底病杂志,1995,11:31.
164 何剑峰,仇宜解,鲍连云,等.枸杞在糖尿病大鼠视网膜组织抗氧化反应中的作用[J].中国中医眼科杂志,1997,7:131
165 郭国华.临床中药辞典[M].长沙:湖南科学技术出版社,1994.344.
166 刘玉莲,杨丛忠.黄芪药理作用概述[J].中国药业2004,13(10):79.
167 吴发宝,陈希元.黄芪药理作用研究综述[J].中药材,2004,27(3):232-234.
168 张汝学,顾国明,张永祥,等.地黄低聚糖对实验性糖尿病与高血糖大鼠糖代谢的调节作用[J].中药药理与临床,1996,12(1):14-17.
169 Yoshida A,Feke GT,Feke GD,et al.A new laser Doppler system for examining optic nerve head circulation J Biomed Opt,1998,3:396-400.
170 Sleova OS,Gerasimenko VA,Makarov V,et al.Comarative atudy of the role of cytokines in different forms of eye diseases.1.Tumor necrosis factor-alhal. [Russian]vestink of talmologii,1998,114:28.
171 黄敬泽,王健,张闾珍,等.血管内皮细胞损伤在Ⅱ型糖尿病血管病变中的意义[J].中华内分泌代谢杂志,2000,3:169.
172 王夏涟,闫德春.研究糖化血红蛋白与糖尿病性视网膜病变的关系[J].医学研究通讯,2000,8:40.
2 史轶繁.内分泌和代谢学[M].北京:科学出版社,2000:1343.
3 Xiang H D.The morbitity of chronic complication of Chinese patiens with DM within 1991 - 2000[J].Diabetes Research and Clinical Practice,2000,56(suppl):841.
4 Nakajima M,Cooney M J,Alexander H T,et Al.Normalization of retinal vascular permeability in experimental diabetes with genistein[J].Invest Ophthalmol Vis Sci,2001,42:2110-2114.
5 康洁.糖尿病视网膜病变发生发展与全身相关因素研究进展,国外医学眼科学分册[J].2004,28(2):107-120.
6 曾庆华.中医眼科学[M]新世纪全国高等中医药院校规划教材(供中医药类专业用).北京:中国中医药出版社,2003:201.
7 金·刘守真,河间医集·黄帝素问宣明论方·卷十·燥门·消渴总论.第1版,北京:人民卫生出版社.1998:288
8 李振中,尹翠梅,痰癖互结与糖尿病血管病变[J].中华新医药,2002(1):2.
9 王明芳,谢学军,中医眼科学[M].北京:中国中医药出版社,2004:740.
10 谢学军,王明芳.糖尿病视网膜病变的病机探讨[J].中国中医眼科杂志,1995,5(2):86-88.
11 梁光宇.冯明清教授治疗糖尿病学术思想简介[J].河南中医,2000,(1):15.
12 李劲亮.消渴明目方治疗早期糖尿病性视网膜病变35例[J].国医论坛,2000,15(6):24.
13 刘求红.余杨桂教授治疗糖尿病性视网膜病变的思路与经验[J].黑龙江中医药,2004,18(2):26-27.
14 李振中,尹翠梅,和贵章.糖尿病性视网膜新生血管病因病机和防治探讨[J].江苏中医,2000,21(3):12.
15 刘红娣 姚芳蔚老师治疗糖尿病性视网膜病变的经验[J].中西医结合眼科杂志,1998,16(4):233-234.
16 文晓敏,丁辉,浅谈糖尿病视网膜病变中瘀血病理机制初探[J].山西中医,2003,24(10):959-960.
17 董立均,邵晓颖,中西医结合治疗糖尿病视网膜病变48例分析[J].吉林中医药,2000,14(6):52.
18 陈通文.糖尿病论治的临床研究进展[J].中国中医药信息杂志,2000,(1):18.
19 李志英,余杨桂,张淳,等.糖尿病视网膜病变与血瘀关系的探讨[J].广州中医药大学学报,1999,16(4):275-278.
20 吕仁和,赵进喜,王世东.糖尿病及其并发症的临床研究[J].新中医,2001,33(3):3-5.
21 朱晓林.健脾祛瘀化痰法治疗糖尿病视网膜病变理论探讨[J].中医药学刊,2005,23(7):1291-1292.
22 祁宝玉,廖岩松,等.糖尿病性视网膜病变的研究思路[J].中国中医眼科杂志,1998,8(1):54-55.
23 李志英,余杨桂,张淳,等.糖尿病中医证型与糖尿病视网膜病变分期关系的探讨[J].中国中医眼科杂志,2000,10(1):29-32.
24 张慧,孙河.糖尿病视网膜病变分级与中医辨证分型关系的临床研究[J].中医药学报,2004,32(4):6-7.
25 苏航,吴烈.糖尿病视网膜病变发展与中医证候特征相关性的临床研究[J].中国中医眼科杂志.2005,15(4):190-192.
26 李传课.中西医结合眼科学[M].北京:中国中医药出版社,2001,8:294-295.
27 董彦敏.糖尿病眼病的防治[M].北京:中国中医药出版社,2003,8:83-85.
28 韦企平.韦玉英眼科经验集[M].北京:人民卫生出版社,2001,10:231-232.
29 姚芳蔚.眼底病的中医治疗[M].上海:上海中医药大学出版社,2001:56-57.
30 刘文华,廖品正.糖尿病视网膜病变的病因及分型论治探讨[J].国医论坛,2001,16(3):15-16.
31 刘红娣.姚芳蔚治疗糖尿病视网膜病变的经验[J].中西医结合眼科杂志.1998,16(4):45-46.
32 高璇,李刚.糖尿病视网膜病变的中医治疗[J].中医药信息,2001,18(3):43.
33 李红,夏建生.糖尿病视网膜病变辩证及分型的临床研究进展[J].河南中医,2000,20(5):33.
34 凌波达.中西医结合治疗糖尿病眼底出血[J].北京中医.1999(3):17.
35 吉敏.中西医结合治疗糖尿病视网膜病变27例[J].吉林中医药.2004,24(8):14-16.
36 倪青.著名中医学家林兰教授学术经验之十一病位侧重肝脾肾治宜祛瘀重养阴-治疗糖尿病视网膜病变的经验[J].辽宁中医杂志,2001,28(5):259-261.
37 吴丹巍,殷长青,郑军,等.辨证分型为主治疗糖尿病视网膜病变临床观察[J].上海中医药杂志,2000,34(6):42-43.
38 高培质,增生型糖尿病视网膜病变的中西医结合治疗[J].中国中医眼科杂志,2001,(4):196-197.
39 黄建良,喻干龙.活血化瘀法治疗糖尿病视网膜病变38例[J].湖南中医杂志,2000,16(1):29.
40 刘韵宇,余元泰,杨国栋,滋阴去瘀法治疗糖尿病视网膜病变[J].兰州医学学报,1999,6,25(2)59-61.
41 罗旭升,高健生,朱旭华,交泰丸防治DR的思路探讨[J].中国中医眼科杂志,2005,15(2),103-104.
42 邓海先,等.宁血益明丸治疗糖尿病视网膜病变远期疗效分析[J].中成药,2003,25(3):209-212.
43 邓辉,金明,苑维,等.复方丹参滴丸治疗早期DR的临床观察[J].中国中医眼科杂志,2005,15(2):36.
44 魏冠男,刘仁波,刘炯.益阴活血明目汤治疗糖尿病性视网膜病变52例总结[J].湖南中医杂志,2007,23(1):7-8.
45 李炳茂,李耀峰,刘慧玲.复方大黄制剂治疗糖尿病视网膜病变200例[J].中医杂志,2000,41(2):119.
46 曹淑兰,孙元荣,张北岳.增视胶囊治疗糖尿病视网膜病变疗效观察[J].山东中医杂志,2000,41(2):281-282.
47 李文东.分期辨证单纯型糖尿病性视网膜病变100例临床观察[J].中国中医药科技,2000,7(3):186-187.
48 增敬.中西结合治疗DR34例[J].吉林中医药.2004,24(8):34-35.
49 林日可.降糖复明汤为主治疗糖尿病眼底病变40[J].浙江中医杂志,2003,38(9):387.
50 刘玲,郭霞.糖目清治疗糖尿病视网膜病变临床总结[J].山东中医药杂志,2000,(3):145.
51 侯建宁.养阴化瘀汤治疗糖尿病视网膜病变50例[J].河北中医,2004,26(8):629.
52 罗恒,余红.递法明片联合降糖愈目汤治疗糖尿病视网膜病变47例[J].中华现代眼科学杂志,2004,1(2):168.
53 焦晓燕,曾佩红.自拟益气通脉汤治疗非增殖期糖尿病视网膜病变临床观察[J].北京中医,2005,24(3):162-163.
54 盛萍.坠血明目饮治疗糖尿病视网膜病变48例[J].河南中医,2006,26(1):53-54.
55 杨建华,段俊国,周春阳.糖网方治疗糖尿病视网膜病变101例[J].河南中医,2003,23(10):37-38.
56 于文洲,张伟.糖视明方治疗DR的临床观察[J].山东中医药大学学报,2000,24(5):361-362.
57 齐翠英.降糖明目合剂治疗糖尿病视网膜病变58例[J].河南中医,2002,22(1):39.
58 杨海燕,杨建华.益气活血方治疗糖尿病视网膜病变61眼临床及彩色多谱勒眼动脉血流频数观察[J].浙江中医杂志,2001,(1):30-31.
59 赵红.辨证治疗糖尿病视网膜病变[J].河南中医,2001,21(3):54.
60 张娟.止血愈消汤治疗糖尿病视网膜病变眼底出血36例[J].浙江中医杂志,2006,41(8):474.
61 黄云飞.中西医结合治疗糖尿病视网膜病变70例疗效观察[J].四川中医,2004,22(8):94.
62 徐寒松,孔德明,李雪梅,等.通脉糖眼明胶囊治疗单纯型糖尿病性视网膜病变临床研究[J].中华中医药杂志,2006,21(9):567-569.
63 蒋莉.熊胆逐瘀片治疗非增殖性糖尿病视网膜病变观察[J].辽宁中医杂志,2001,28(4):213-214.
64 孙河,郝晓楠.达明饮治疗糖尿病视网膜病变的临床观察[J].中华医学会第十界全国眼科学术大会论文汇编,2005,9.8-12.
65 于强,张欣,柳青.达纳康对糖尿病视网膜病变眼视网膜光凝术所致眼前段早期改变的干预效果[J].中华眼底病杂志,2001,17(3):187-189.
66 任平,胡惠君,张瑞.葛根素治疗糖尿病视网膜病变的疗效观察[J].中国中西医结合杂志,2000,20(8):574-576.
67 郭俊杰,尹翠梅.葛根素注射液治疗单纯型糖尿病视网膜病变38例[J].中国中医药信息杂志,2001,8(10):57-58.
68 相莉,吴谊青,刘新玲.络泰治疗糖尿病视网膜病变[J].中草药,2000,(4):319.
69 何剑峰,周伟平,仇宣解.糖尿病视网膜病变患者红细胞免疫功能的变化及枸杞子的治疗效应[J].中国中医眼科杂志,1998,8(2):70-73.
70 左宏宇.川芎嗪治疗单纯型糖尿病视网膜病变的临床观察[J].临床眼科杂志,2005,13(3):258-259.
71 唐爱华,史伟,唐农,等.黄芪注射液治疗单纯性糖尿病视网膜病变临床研究[J].浙江中医杂志,2002,38(4):176-177.
72 王为,靡亚兵,陈宝安.汉防己甲素在眼科的基础研究进展[J].中国中医眼科杂志,2001,(1):59-61.
73 郑燕林,王毅,袁晓辉,等.水蛭素对增生性玻璃体视网膜病变影响的组织病理学观察[J].中国中医眼科杂志,2000,10(1):1-3.
74 王坚,陈敏,李晓冬,等.葛根素大黄素对糖基化产物引起牛视网膜微血管周细胞损伤的影响[J].中药药理与临床,2000,16(6):9-10.
75 鹿庆,孙褒忱,王津津.人参皂甙和维生素对氧化损伤的牛细胞凋亡的影响[J].眼科新进展,1999,19(3):152-154.
76 陈少基,李树成.综合治疗单纯性糖尿病视网膜病变的临床研究[J].中国中医眼科杂志,2005,15(2):69-71.
77 刘学敏.针药并用治疗糖尿病视网膜病变60例临床观察[J].上海中医药杂志,2002(2):23.
78 许云祥,张家继.针刺治疗糖尿病研究思路[J].针刺研究,2000,(2):156.
79 呼永河,吴深涛.针药结合治疗糖尿病视网膜病变40例临床观察[J].中国针灸,2003,23(5):259-260.
80 林兰.糖尿病的中西医结合论治,第一版,北京北京科学技术出版社,1998,18(3):138.
81 李菊琦,耳针中药治疗糖尿病性视网膜病变近期观察,河北中医,1998,20(2):8-11.
82 王德全,刘国真,李永春.针刺治疗糖尿病视网膜病变的实验研究[J].中国中医眼科杂志,2000,(3):125-128.
83 姜士军,曹晋宏.川芎嗪离子导入治疗糖尿病视网膜病变疗效观察[J].国际眼科杂志,2006,6(4):941-942.
84 王燕,李志英,余杨桂,等.中药配合眼部川芎嗪直流电离子导入治疗糖尿病视网膜 病变74例疗效观察[J].新中医,2006,38(1):42-43.
85 宋明强,马国政.川芎嗪、维生素B12交替离子导入法治疗糖尿病视网膜病变疗效观察[J].医学理论与实践,2005,18(8):905-907.
86 Asthton N.Vascular basement memberane changes in diabetic retinop2athy[J].Br J Ophthalmol,1974,58:344-366.
87 朱禧星.现代糖尿病学[M].上海:上海医科大学出版社,2000.307-309.
88 Paques M,Massin P,Gaudric A.Growth factors and diabetic retinopa2thy[J].Diabetes Metab,1997,23(2):125-130.
89 Takagi H.Molecular mechanisms of retinal neovascular in diabetetic retinopathy.Intern Meal,2003,(42):299-301.
90 Lieth E,Barber AJ,Xu B,et al.Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy[J].Diabetes,1998,47(5):815-820.
91 Amin RH,Frank RN,Kennedy A,Eliott D,Puklin JE,Abrams GW.Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.Invest Ophthalmol Vis Sci 1997;38:36-47.
92 Lutty GA,McLeod DS,Merges C,Diggs A,Plou(?)t J.Localization of vascular endothelial growth factor in human retina and choroid.Arch Ophthalmol 1996;114:971.
93 Clermont AC,Alello LP,Mori F,et al.Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy medicate retinal hemodynamics in vivo:a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy[J].Am J Ophthalmol,1997,124(4):433-446.
94 侯承花,刘成玉.糖尿病视网膜病变与红细胞变形能力和膜磷脂及收缩蛋白变化的关系[J].中华眼底病杂志,1999,15(3):160-162.
95 何剑峰,仇宜解,周行涛,等.糖尿病视网膜病变与白细胞粘附及变形能力关系的研究[J].眼科研究,2000,18(6):533-535.
96 郭慧丽,付晓美,鲁平,等.载脂蛋白A1、B与糖尿病视网膜病变关系的研究[J].眼科研究,2000,18(5):454-455.
97 Li W,Zhou Q,Qin M,et al.Reduced absolute rate of myo-inositol synthesis of cultured bovine retinal capillary pericytes in high glucose[J].Exp Eye Res,1991,52:569-573.
98 Pfeifer MA,SchumerMP,GelberDA.[J].Diabetes,1997,46(Supp12):82-89.
99 Neuenchwander H.Dose-dependent reduction of retinal vessel changes associated with diabetic retnopathy in galactose-fed dogs by the aldose reductase inhibitor M79175[J].J Ocul Pharmacol Ther,1997,13:517.
100 Alan W,Stit T.The role of advanced glycation in the pathogensis of diabetic retinopathy.Exp Mol Pathology,2003;75:95-108.
101 隋国良,葛在香,董砚虎.糖尿病视网膜病的发病机制及其防治研究进展[J].国外医学·内科学分册,2000;27(3):119-122.
102 李媛,卢艳.糖尿病视网膜病变早期发病机制研究进展[J].国际眼科杂志,2005;5(4):750-754.
103 张小玲,邱曙东,陈艳烔,孙文涛.糖尿病性视网膜病变发病机制研究进展[J].国际眼科杂志.2005;5(6):1239-1241.
104 朱鸿,施彩虹.糖尿病视网膜病变的相关诊断技术展望[J].国际眼科杂志,2005;5(5):1016-1019.
105 Stitt AW,LiYM,GardinerFA,et al[J].Am J Pathol,1997,150(2):523-531.
106 King GL,Shiba T,Oliver J,et al.Cellutar and molecular abnormalities in the vascular endothelium of diabetes mellitua[J].Annu Rev Med,1994,45:175.
107 Ono Y,Umeda F,Kunisaki M,et sl.[J].Diabetologia,1998,41:134-140.
108 Aiello OP,Bursell SE,Clermont A,et al.[J].Diabetes,1997,46:1473-1480.
109 Takag I,Bursell SE,Lin YW,et al.[J].Invest Ophthalmol Vis Sci,1996,37:2504-2518.
110 Hodgkinson AD,Bartlett T,Oates PJ,et al.The response of antioxidant genes to hyperglycemia is abnomal in patients with type 1 diabetes and diabetic nephropathy[J].Diabetes,2003,52:846-851.
111 廖宇洁.氧化应激与糖尿病视网膜病变[J].眼科研究,2007,25(9):710-713.
112 Kowlru RA,Tang J,Kem TS.Abnomalities of retinal metabolism in diabetes and experimental galactosemia.Ⅶ.Effect of long-term administration of antioxidants on the development of retinopathy[J].Diabetes,2001,50,1938-1942.
113 Christinger H W.Crystallization of the receptor binding domain of vascular endothelial growth factor[J].Prteins,1996,26:353-354.
114 Kuroki M,Kawakami M.Diabetic retinopathy-the mechanisms of the ocular neovascularization and development of antiangiogenic drugs[J].Nippon Rinsho,1999,57:584-589.
115 Dawson DW,Volpert OV,Gillis P,et al.Pigment epithelium-derived factor:a potent inhibitor of angiogenesis.Science 1999;285:245.
116 Gao G,Li Y,Zhang D,Gee S,Crosson C,Ma J.Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization.FEBS Lett 2001;489:270.
117 Smith LE,Shen W,Perruzzi C,et al.Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1receptor.Nat Med 1999;5:1390.
118 Smith LEH,Kopchick JJ,Chen W,et al.Essential role of growth hormone in ischemia-induced retinal neovascularization.Science 1997;276:1706-9.
119 Parlapiano C.Study of plasma levels of endothelin - 1 in diabetic patients with arterial hypertension or proliferative retinopathy[J].Minerva Med,1995,86:105.
120 黄敬泽,张珍,王健.外周血循环内皮细胞、血浆内皮素与糖尿病视网膜病变的关系[J].中华眼底病杂志,2000;16(3):1661.
121 胡蜀红,张建华,蔡仕林.糖尿病视网膜病变与血浆内皮素的关系[J].临床荟萃,2003;18(12):677-678.
122 Joussen AM,Poulaki V,Qin W,Kirchhof B,Mitsiades N,Wiegand SJ.Retinal vascular endothelial growth factor induces synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.Am JPathology,2002;160:501-509.
123 Ishida S,Usui T,Yamashirok,Kaji Y,Ahme-d E.VEGF 164 is proinflammatory in the diabetic retina.Invest Opthalmol VisSci,2003;44:2155-2162.
124 Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid.Am J Pathol,1995;147(3):642-653.
125 Mackay C R,Imhof B A.Cell adhesion in the immune system[J].Immunol Today,1993,14:99-102.
126 RadhaV,RernaM,MohanV.Genes and diabetic retinopathy.Indian J Ophthalmol,2002,50:5-11.
127 JoussenAM,Huang S,PoulakiV,etal.In vivoretinalgene expression in early diabetes.Invest Ophthalmol Vis Sci 2001;42(12):3047-3057.
128 刘卫,张勇进.糖尿病性视网膜病变[J].国外医学眼科学分册2005;29(5):352-357.
129 Wilkinson CP,Ferris FL Ⅲ,Klein RE,LeePP,Agardh CD,Davis M.Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.Ophthalomlogy,2003;110(9):1677-1682.
130 刘家琦,李凤鸣.实用眼科学[M].第2版.北京:人民卫生出版社,1999.481.
131 The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 1993;329:977-86.
132 UK Prospective Diabetes Study(UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes(UKPDS 33).Lancet 1998;352:837.
133 Idem.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38.BMJ 1998;317:703-13.
134 Faria JM,Russ H,Costa VP.Retinal nerve fibre layer loss in patients with type 1diabetes mellitus without retinopathy[J].Br J Ophthalmol,2002,86(7):725-728.
135 Brunet J,FarineJC,Garray RP,et al.Angioprotective adtion of calcium dobesilate [J].Fundam Clinpharmacol,1998,12(2):205-212.
136 王另芳,段俊国,张富文.导升明治疗糖尿病性视网膜病变的概况[J].临床眼科杂志,2002,10(2):188-189.
137 M asakazu M et al.The effect of high glucose and aldose reductase inhibitor(FK 366) on myo-inositol uptake in cultured bovine pericyte[J].D iabetes,1998;47(supp 11):A 379.
138 Pfeifer MA et al.Aldose reductase inhibitors:the end ofan era or the need for different trial designs? D iabetes,1997;46(supp 12):S82.
139 罗大卫,许讯.氨基胍与糖尿病视网膜病变[J].眼科新进展,2002,22(3):206.
140 Giardino I et al.Am inoguanidine inhibits reactive oxygen species formation,lipid peroxidation,and oxidant2inducedapop to sis.Diabetes,1998;47:1114.
141 Kern TS,Tang J,Mizutani M,et al.Response of capillary cell death to aminoguanidine predicts the development of retinopathy:comparison of diabetes and galactosemia[J].Invest Ophthalmol Vis Sci,2000,41(12):3972-3978.
142 朱禧星.现代糖尿病学[M].上海:上海医科大学出版社,2000.307-309.
143 Nonaka A,Kiryu J,Tsujikawa A,et al.PKC-beta inhibitor(LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rars[J].Invest Ophthalmol Vis Sci,2000,41(9):2702-2706.
144 Ish ii H et al.Amerlio ration of vascular dysfunctions indiabetic rats by an oral PKC2B inh ibito r.Science,1996;272:728.
145 黄红深.增殖性糖尿病视网膜病变的治疗[J].临床眼科杂志,2002,10(2):146-147.
146 Infeld DA,O'Shea J G.Diabetic retinopathy[J].Postgrad Med J,1998,74:129-133.
147 Cunha Vaz J.Lowering the risk of visual impairment and bindness[J].Diabet Med,1998,15(Supp14):47-50.
148 Fong DS,Ferris FL,Davis MD.Causes of severe visual loss in the early treatment diabetic retinopathy study:ETDRS report no.24 Early Treatment Diabetic Retinpathy Study research group[J].Am Ophthalmol,1999,127(2):137-141.
149 郑筱萸,中药新药治疗糖尿病视网膜病变的临床研究指导原则,北京:中国医药科技出版社.2002,383-385.
150 Klein R,Klein BEK,Moss SE,Davis MD,DeMets DL.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.Ⅱ.Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.Arch Ophthalmol 1984;102:520-6.
151 Idem.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.Ⅲ.Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.Arch Ophthalmol 1984;102:527-32.
152 王平.三七对血液系统作用的研究进展[J].中国野生植物资源,2000,19(1):10.
153 许军,王阶,温林军.三七总皂甙干预血栓形成研究概况[J].云南中医中药杂志,2003,24(5):46.
154 潘莹宇,张建新.中草药活性成分对实验性糖尿病降糖效的研究进展[J].东南大学学报(医学版),2003,22(6):42924.
155 吕萍,陈海峰.三七叶苷降脂作用的实验研究[J].中国生化药物杂志,2004,25(4):235-236.
156 Gibbs A,Greec E,Doctor VM,et al.Isolation and aticoagulant propertiec of polysaccharides of typha angustata and dae monoropsspecies[J].Thromb Res,1983,32(2):27.
157 刘斌,陆蕴如,孙建宁.蒲黄不同炮制品药理活性的比较研究[J].中医药报,1998,20(3):25.
158 王丽君,廖矛川,肖培根.中药蒲黄的化学与药理活性[J].时珍国药研究,1998,9(1):49-50.
159 郑虎占,董泽宏,佘靖,等.中药现代研究与应用,第5卷[M].北京:学苑出版社,1998:4071-4074.
160 全国中草药汇编编写组.全国中草药汇编,上册,第2版[M].北京:人民卫生出版社,2000:800-802.
161 杨新波,黄正明,曹文斌,等.枸杞多糖对正常小白鼠及四氧嘧啶致高血糖的影响[J].人民医药学专刊,1998,14(1):11-13.
162 黄正明,杨新波,曹文斌,等.枸杞多糖对小鼠链佐星性胰岛损伤及血糖的影响[J].世界华人消化杂志,2001,9(12):1419-1421.
163 刘娜,李子良,曹安民.枸杞在保护大鼠视网膜光损伤中作用的研究[J].中华眼底病杂志,1995,11:31.
164 何剑峰,仇宜解,鲍连云,等.枸杞在糖尿病大鼠视网膜组织抗氧化反应中的作用[J].中国中医眼科杂志,1997,7:131
165 郭国华.临床中药辞典[M].长沙:湖南科学技术出版社,1994.344.
166 刘玉莲,杨丛忠.黄芪药理作用概述[J].中国药业2004,13(10):79.
167 吴发宝,陈希元.黄芪药理作用研究综述[J].中药材,2004,27(3):232-234.
168 张汝学,顾国明,张永祥,等.地黄低聚糖对实验性糖尿病与高血糖大鼠糖代谢的调节作用[J].中药药理与临床,1996,12(1):14-17.
169 Yoshida A,Feke GT,Feke GD,et al.A new laser Doppler system for examining optic nerve head circulation J Biomed Opt,1998,3:396-400.
170 Sleova OS,Gerasimenko VA,Makarov V,et al.Comarative atudy of the role of cytokines in different forms of eye diseases.1.Tumor necrosis factor-alhal. [Russian]vestink of talmologii,1998,114:28.
171 黄敬泽,王健,张闾珍,等.血管内皮细胞损伤在Ⅱ型糖尿病血管病变中的意义[J].中华内分泌代谢杂志,2000,3:169.
172 王夏涟,闫德春.研究糖化血红蛋白与糖尿病性视网膜病变的关系[J].医学研究通讯,2000,8:40.